old WP ej via Cision

Isofol Strengthens Executive Management Team with the Appointment of Roger Tell, MD, PhD, as Chief Scientific Officer and Senior Vice President of Clinical Development

GOTHENBURG, Sweden, November 19, 2018 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced the recruitment of Roger Tell, MD., PhD as Chief Scientific Officer (CSO) and Senior Vice President (SVP) of clinical development. Dr. Tell has more than a decade of experience as a clinical oncologist in addition to holding management …

Isofol Strengthens Executive Management Team with the Appointment of Roger Tell, MD, PhD, as Chief Scientific Officer and Senior Vice President of Clinical Development Read More »

Isofol Announces Initiation of a Pivotal Phase 3 Clinical Trial of arfolitixorin for the Treatment of Metastatic Colorectal Cancer

GOTHENBURG, Sweden, November 15, 2018 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL) today announced initiation of the pivotal Phase 3 clinical trial, the ISO-CC-007 study, for the treatment of first-line (initial) metastatic colorectal cancer (mCRC). Anders Rabbe, chief executive officer of Isofol, said, “We look forward to bringing arfolitixorin to all patients …

Isofol Announces Initiation of a Pivotal Phase 3 Clinical Trial of arfolitixorin for the Treatment of Metastatic Colorectal Cancer Read More »

New Chairman and extended board at Isofol Medical AB (publ)

Isofol Medical AB (publ), developing arfolitixorin as treatment for advanced colorectal cancer is calling an Extraordinary General Meeting on Wednesday 10 October. The present Chairman, Jan-Eric Österlund, is resigning and the Nomination Committee is proposing Dr Ulf Jungnelius as new Chairman. The Committee is also proposing an increased board with three new directors.   Isofol’s …

New Chairman and extended board at Isofol Medical AB (publ) Read More »

Isofol Medical adopts the World Health Organization recommended name (INN) arfolitixorin for Modufolin®

Isofol Medical AB (publ) today announce that the company will in the future be adopting the generic name arfolitixorin for its lead candidate, up to now referred to as Modufolin®. Arfolitixorin was recently accepted by  World Health Organization (WHO) as the International Non-proprietary Name (INN) for the active ingredient of Isofol’s lead product Modufolin®. “We …

Isofol Medical adopts the World Health Organization recommended name (INN) arfolitixorin for Modufolin® Read More »

Scroll to Top